Patricia Imbach
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Biochemical and Molecular Research, Peptidase Inhibition and Analysis, Glycosylation and Glycoproteins Research, Cancer-related Molecular Pathways
Most-Cited Works
- → Ethnobotanical-Directed Discovery of the Antihyperglycemic Properties of Cryptolepine: Its Isolation from Cryptolepis sanguinolenta, Synthesis, and in Vitro and in Vivo Activities(1998)133 cited
- → The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis(2010)125 cited
- → Antihyperglycemic Activities of Cryptolepine Analogues: An Ethnobotanical Lead Structure Isolated fromCryptolepis sanguinolenta(1998)104 cited
- → 2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors(1999)82 cited
- → DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance(2024)76 cited
- → Entry into a New Class of Potent Proteasome Inhibitors Having High Antiproliferative Activity by Structure-Based Design(2004)55 cited
- → Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison(2010)43 cited
- → Structure-based design of potent CDK1 inhibitors derived from olomoucine(2000)35 cited
- → Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design(2001)29 cited
- → A New Structural Class of Selective and Non-covalent Inhibitors of the Chymotrypsin-like Activity of the 20S Proteasome(2001)26 cited